Thursday, August 25, 2016

Update on EpiPens

Many people who could die without an EpiPen now can't afford one! Tell Big Pharma to immediately reduce the cost of this life-or-death treatment.

Dear MoveOn member,

Next week, we're delivering more than 200,000 signatures to pharmaceutical company Mylan's corporate headquarters to fight back against EpiPen price-gouging. There's still time to make sure your name is included: Click here to sign the petition now.

EpiPen creator Mylan just responded to public outrage over its price-gouging by offering discount cards. But this false solution can be summed up as too little, too late and will leave many families paying more than $300 out of pocket.1 If Mylan wants to act responsibly in the wake of this public outrage over its contemptible and unconscionable price spikes for EpiPens, there's only one course of action: Actually lower the price.

Keep up the pressure on Mylan and tell the CEO: Stop price-gouging customers who rely on the EpiPen! Click here to sign your name alongside 200,000 MoveOn members who have already taken action, and it'll be delivered in-person next week.

Thanks for all you do.

—Robert Weissman
President, Public Citizen

P.S. You can read the original, urgent note from MoveOn member Debbie Pierce below.

Tell Mylan CEO Heather Bresch: Stop price-gouging the EpiPen now.

Stop price-gouging the millions of people who need an EpiPen to save their lives if they have a severe allergic reaction.

Dear fellow MoveOn member,

My son will die without an EpiPen—he literally has less than 10 minutes to get to a hospital with the pen. But Mylan, the multinational company that makes this life-saving drug, just ruthlessly raised the price. I can't afford to buy new pens at $300 per year, and the ones he already has expire in a couple of months. Pharmaceutical companies must stop this greedy price gouging now. 

Will you join me in signing the petition to Mylan CEO Heather Bresch asking the company to stop price-gouging the EpiPen immediately?

Millions of children and adults in the U.S. are at risk of fatal allergic reactions from common occurrences, like getting stung by a bee or accidentally consuming peanuts.

A pocket-sized medical device called an EpiPen can be a literal life-saver for people with severe, life-threatening allergies.

But Mylan—the multinational pharmaceutical company that makes the EpiPen—has been steadily jacking up its price.

  • In 2007, the wholesale price of an EpiPen in the U.S. was $57.2
  • Today, just nine years later, it's over $300.3
  • Even though each EpiPen contains only $1 worth of medicine.4
  • Even though a two-pack is just $85 in France.5
  • And even though Mylan, which has a near monopoly in the U.S., has seen its profits from the EpiPen alone skyrocket to $1 billion a year.6

Now, many people, like my son, could actually die because they can't afford an EpiPen!

Tell Mylan CEO Heather Bresch to immediately reduce the cost of this life-or-death treatment that so many people depend on.

Click here to add your name to this petition, and then pass it along to your friends.


—Debbie Pierce


1. "Mylan’s Announcement on EpiPen Prices: Too Little Too Late," Public Citizen, August 25, 2016

2. "Senators Scrutinize Mylan Over EpiPen’s U.S. Price Increases," Bloomberg, August 22, 2016

3. "EpiPen Price Rise Sparks Concern for Allergy Sufferers," The New York Times, August 22, 2016

4. "How Marketing Turned the EpiPen Into a Billion-Dollar Business," Bloomberg, September 23, 2015

5. Ibid.

6. Ibid.

You're receiving this petition because we thought it might interest you. It was created on, where anyone can start their own online petitions. You can start your own petition here.

Want to support our work? MoveOn member contributions have powered our work together for more than 17 years. Hundreds of thousands of people chip in each year—which is why we're able to be fiercely independent, answering to no individual, corporation, politician, or political party. You can become a monthly donor by clicking here, or chip in a one-time gift here.

No comments:

Post a Comment